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ABSTRACT 
Purpose: To ascertain whether and how recontacting occurs in the UK. 
Method: A web-based survey was administered online between October 2014 and July 
2015. A link to the survey was circulated via an email invitation to the clinical leads of the 
UK’s 23 clinical genetics services, with follow-up with senior clinical genetics staff. 
Results: The vast majority of UK services reported that they recontact patients and their 
family members. However, recontacting generally occurs in an ad hoc fashion when an 
unplanned event causes clinicians to review a file (a ‘trigger’). There are no standardised 
recontacting practices operating in the UK. More than half of the services were unsure 
whether formalised recontacting systems should be implemented. Some suggested greater 
patient involvement in the process of recontacting. 
Conclusion: This research suggests that a thorough evaluation of the efficacy and 
sustainability of potential recontacting systems within the national health service would be 
necessary before deciding whether and how to implement such a service or to create 
guidelines on ‘best practice’ models. 
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INTRODUCTION 
The problem  
The increasing introduction of new genetic technologies in the investigation of patients is 
creating much new information. This raises important issues related to the communication 
of the potential health significance of new findings (e.g., new information about the natural 
history of a condition; surveillance or treatments available; improved diagnostic accuracy, 
such as a new test; or new information about previously uncertain test results, such as 
classification of a VUS - variant of unknown significance). This might mean that patients 
seen and tested in the past could now be offered more informative testing. As a result, 
questions may arise about whether healthcare professionals, such as clinical genetics 
specialists, have a responsibility or duty to recontact former patients.  Innovations in 
genomic medicine can have significant implications for patients and families as regards 
health, reproductive decisions, lifestyle choices, employment, and psychosocial wellbeing. 
However, recontacting patients may also affect them negatively, potentially causing anxiety 
and concerns over health and economic activity, and being experienced as an intrusion into 
privacy [1]. While recontacting patients has been raised as a major issue in medical genetics, 
its importance will become even more widespread with the increasing integration of 
genomics in medicine [2]. Clarifying the issue of whether and how recontacting in clinical 
genetics should be implemented is of importance to the current information revolution in 
healthcare [3]. 
Policy/guidelines  
There is no professional consensus in clinical genetics about whether, and how, former 
patients should be recontacted when new genetic information relevant to them or their 
family members arises from the use of new technologies. A survey of regulations and 
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practices of genetic counselling in 38 European countries found that recontacting was 
amongst the least covered topics in both national legislation and applied practice guidelines 
[4].  
The only guideline currently available is a statement originally published in 1999 by the 
American College of Medical Genetics [5]. This document highlights the logistical difficulties 
of locating and recontacting former patients, and identifies the primary care provider (the 
specialist tasked to provide continuing care, such as the GP in the UK NHS) as the principal 
responsible healthcare provider to alert their patients to the need for recontact if necessary. 
Genetic service providers would be responsible to give clinical updates to patients in the 
rarer cases in which they are offering continuing care. The statement also suggests that 
patients should be appropriately advised to update their primary care provider or the 
genetic service provider if relevant changes in their lives occur, such as pregnancy [5]. The 
2008 revision of the statement recognises that with the uptake of next generation 
sequencing, testing laboratories may now be in a position to know about changes in 
interpretation of variants whose significance had previously been unknown (former VUS), or 
about reclassifications of previously classified variants – and should make an effort to 
contact relevant healthcare providers  if new information changes the previous clinical 
interpretation of a sequence variant [6].  
Systematic review of recontacting literature 
The only systematic review of recontacting literature [7] identified 61 articles published 
between 1991 and 2014 which explore ethical, legal, social, psychological, clinical, and 
practical issues. The review identified a divergence of expectations about who is responsible 
for keeping patients up-to-date with relevant information. While patients tend to assign this 
responsibility solely to healthcare professionals – especially genetic service providers – 
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healthcare professionals tend to think this responsibility should also be shared by patients 
[8-10].  
The review also showed that although most patients want to be recontacted, not all do, 
because of the potential for strong emotional reactions to such recontact [11, 12]. 
Most authors identified a clash between the ethical desirability and the practical difficulty of 
recontacting. The most common practical barriers to recontacting mentioned are lack of: 
infrastructures for tracking data of former patients (e.g., digitalisation of databases) [13]; 
time and resources (e.g., staff, money) to perform recontacting [8, 9, 14]; not having 
patients’ current address details [15]. 
Suggestions to overcome these barriers include: implementing digital communication 
systems between laboratory, clinicians, and patients [14]; involving patients in the processes 
of recontacting [10, 16]; involving patient support or advocacy groups [8, 17].  
Need for more empirical evidence  
The authors of the systematic review suggest that more empirical evidence is needed to 
advance the discussion over whether and how recontacting should be implemented [7]. 
There is limited empirical evidence concerning the perspectives of healthcare professionals 
and patients on recontacting or what is occurring in clinical practice. There is an urgent need 
for more research on the practical and ethical implications for healthcare systems of 
recontacting recommendations or guidelines. To begin to provide such empirical evidence, 
we have conducted a survey of clinical genetic services in the United Kingdom about their 
current recontacting practices.  
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METHODS 
The Survey 
The survey we conducted is part of an ongoing study which investigates the place of 
recontacting in current clinical practice in the NHS in the UK; the ethical, legal and social 
issues raised; and the expectations of patients and healthcare professionals concerning 
recontacting (Study webpage: http://ex.ac.uk/mgc). The main objective of the survey 
reported here was to ascertain whether and how recontacting occurs in the UK. The topic 
areas were identified from debates in the relevant literature. The questions were developed 
from relevant literature, the clinical experience of members of the research team, and a 
pilot survey on recontacting conducted by some members of the team in 2011 as part of the 
‘Development of a draft NHS Information Standard for Genetics’ by the National Genetics 
Reference Laboratory in Manchester, England1. The questions were further refined by pilot 
testing the survey with clinical genetics service providers.   
The web-based survey was designed using Bristol Online Survey (BOS) and it was 
administered between October 2014 and July 2015. A link to the survey was circulated via 
an email invitation to the clinical leads of the UK’s 23 clinical genetics services, with a follow-
up email to senior clinical genetics staff. The ‘landing page’ of the survey contained 
information about the study and the research team, and invited respondents to discuss the 
survey with colleagues in their service before completing it. 
The survey included closed and open questions with expandable text boxes to elicit 
explanatory comments, and examples. This combination of closed and open questions 
allowed the research team to collect both quantitative and qualitative data. Free text 
                                                          
1
 http://www.ngrl.org.uk/Manchester/newsitem/project-develop-draft-nhs-information-standard-genetics-
launched  
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responses from the survey were analysed using thematic analysis [18]. The survey is 
appended as an online resource.  
Research Ethics approval 
The study was approved by the University of Exeter’s Social Sciences and International 
Studies Ethics Committee.  
RESULTS 
Respondent characteristics  
Twenty of the twenty-three clinical genetics services in the UK2 completed the survey and 
were from all four nations comprising the UK. Of the twenty respondents who completed 
the survey (one per service), nine were consultant geneticists, seven were consultant 
genetic counsellors and the remaining four were genetic counsellors.  
Recontacting experiences and practices 
The vast majority of the services (19/20) reported having recontacted patients and relevant 
family members in light of significant new information. However, 16/20 services indicated 
that recontacting occurred on an occasional basis. Only three services reported that they 
routinely recontact former patients.  
A variety of reasons for having recontacted patients were reported (see Table 1). The most 
common were: the availability of new tests or new results; new clinical guidance; and 
reclassification of a VUS. The table below (table 1) reports the main themes from 
respondents’ answers with some quotations to illustrate each theme. 
 
                                                          
2
 For a complete list of clinical genetics services in the UK visit:  http://www.bsgm.org.uk/information-
education/genetics-centres/. Please note that this list includes also laboratories.  
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[Table1] 
Only seven services responded that they have developed recontacting procedures; three of 
these were the centres who responded that they recontact former patients routinely.   
The procedures reported varied across these centres with no significant pattern.  Common 
across these responses was the mention of a lack of a codified procedure for recontacting.  
Two centres reported that they inform the patients’ general practitioner (GP) or 
paediatrician as appropriate; while two others reported that they inform the patient directly 
(via letter or telephone call). The three remaining centres mentioned that they use clinical 
databases which are held by NHS services (when undergoing testing, patients are consented 
about being on the database and about whether they wish to be recontacted).  However, 
one of these three centres added that they were experiencing problems with their clinical 
databases – as a result of having moved to electronic notes – and that they were using 
external databases as well.  
Recontacting ‘Triggers’  
We asked about the type of information that would be sufficiently relevant to trigger 
recontacting (giving the example of relevance being based on clinical actionability of the 
information, or on its analytic validity). The majority of the services (14/20) indicated that 
one of the most important elements would be clinical actionability- i.e., information that 
has an impact on the clinical management of the patient and their family. One service added 
that in practice they would recontact only if new information relates to a small group or an 
individual patient, because of the workload of recontacting large numbers of patients. Other 
common answers included the publication of new or revised guidelines or new laboratory 
reports.  
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Use of clinical databases  
The majority of the responding centres (18/20) use existing clinical databases, rather than 
bespoke recontacting systems for recontacting purposes. Of these, nine answered that they 
use the databases mainly to identify patients; the other nine used them to review notes 
and/or to flag patients for recontacting.  The clinical databases respondents referred to are 
databases held by the UK NHS. They are mainly used for clinical purposes, but sometimes 
they can be used to identify patients for research. Their current format is mixed (some 
centres use electronic versions, others paper-based versions). 
 
Recording of patient preferences 
The majority of services (12/20) indicated they do not routinely ask patients about their 
recontacting preferences as part of the procedure for obtaining informed consent for 
genetic testing. Of these, six services responded that they record patients’ recontacting 
preferences systematically, six that they do so only occasionally, while the remaining eight 
responded that they do not record patients’ preferences at all.  
Consent forms for genetic testing vary across the services in the UK. Six services said they 
used consent forms that give the option to patients to express their recontacting 
preferences. However, as one of these respondents added, consent forms are not always 
used in clinical practice.  
[Table2] 
Seven services stated that the main reasons for not recording patients’ preferences – or for 
not mentioning the possibility of recontact to patients at all – were lack of resources 
available to offer a recontacting service and concern about raising unrealistic expectations 
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in patients. Four services mentioned their  ‘open door policy’ – whereby clinicians 
encourage the patient to get back in touch with the genetics department from time to time 
to check if there are advances or to update clinicians about important changes in the family.   
When asked hypothetically if there were reasons to recontact patients even when patients 
had indicated they would not want to be recontacted, a majority of services (14/20) 
responded that they would. In line with previous answers about the type of information that 
would trigger recontacting, the main reason provided was new information that may have 
clinical implications for patients and family members. The GP was explicitly mentioned by 4 
respondents as a (first) point of contact to involve in this process. One respondent argued 
that patients’ decisions not to be recontacted could not necessarily anticipate the specific 
information subsequently available, and might therefore be an insufficiently informed 
refusal.  
Of the six services stating that they would respect patients’ preference not to be 
recontacted, one added that if new information was likely to have significant implications 
for a family member, they would inform the patient’s GP; while two mentioned the 
possibility of  seeking external advice (e.g., from the Medical Defence Union, or the 
Genethics Club3). One respondent also made the point that although patients should not be 
recontacted if they clearly expressed this preference, in practice very few patients would be 
definite about their preferences. 
Implementation of recontacting systems  
A slim majority of services (11/20) were unsure about whether routine recontacting systems 
                                                          
3
 The UK Genethics Club is a national forum for the discussion, by health professionals, of practical ethical 
problems encountered in the working lives of clinical genetics departments in the United Kingdom. 
http://www.ndph.ox.ac.uk/research/ethox-centre/ethics-support/genethics-club  
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should be implemented. Of the remaining, five services indicated that they should be 
implemented, while four responded that they should not be. 
The main arguments in favour of implementing systems for recontacting revolved around 
the ideas that this would improve the quality of care received by patients; it would increase 
patients’ autonomy; and it may reduce the potential for litigation. We report below some 
illustrative quotations:  
“New information may help reduce the risk of disease/mortality to other family 
members- e.g. where a mutation is identified - screening and treatment may be 
offered to those at risk”. 
“Technology and knowledge are increasing rapidly and what was known or possible 
even a short time ago may well be different and allow individuals more choice or 
better risk assessment or treatment” 
 One respondent also made the point that clinical genetics would be the only medical 
speciality in a position to offer recontacting. Another respondent highlighted that having 
recontacting mechanisms in place would facilitate the process. 
Among arguments against the implementation of recontacting systems, lack of resources 
was again mentioned and linked to equitable provision of services within the NHS.  Another 
common argument was that patients should be encouraged to be more responsible for their 
health and share the responsibility with clinicians to keep up to date about relevant medical 
information.  
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Legal implications were also mentioned as an argument against the implementation of 
recontacting systems. Specifically, the concern was that introducing such systems would 
create a standard practice and that failure to recontact could then be seen as negligent.  
Concern was also expressed by one service that recontacting might cause anxiety for 
patients and family members; while another service mentioned that recontacting would be 
more difficult to implement as genetic testing is increasingly ordered  by mainstream 
medical specialities.  
Finally, one service said that the time frame for recontacting responsibilities would need 
clarification; for example, for how many years from the genetic test would such a 
responsibility apply?  
DISCUSSION 
This was the first study in the UK to explore current recontacting practices in clinical genetic 
services.  
Recontacting occurs, but on an ad hoc basis 
The vast majority of UK services reported that they do recontact patients and family 
members, confirming the significance of recontacting for good quality of care in clinical 
practice. The majority of respondents indicated that ‘clinical actionability’ of the new 
information is the main reason to recontact. Respondents’ answers also suggest that 
recontacting is becoming more important as clinical whole genome approaches deliver 
many more genetic variants for interpretation.   
Recontacting tends to occur in an ad hoc fashion when an event ‘triggers’ clinicians to 
review a file, rather than systematically as part of routine clinical practice.  
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Procedures vary greatly across the UK 
Our findings suggest that there are no standardised recontacting practices operating in the 
UK. This diversity may be the result of historical and resources allocation differences. Overall 
the fact that recontacting does occur, but not in a standardised fashion, reflects the tension 
identified in prior research between the desirability of recontacting and the current lack of 
mechanisms and resources to offer it more systematically, or at all, resulting in unequal 
recontacting service provision across the country [8, 19]. Only a few centres that recontact 
patients have developed systematic recontacting procedures, but these procedures vary.  
We also found considerable diversity of practice in the use of clinical genetic databases for 
recontacting purposes (e.g., to retrieve patients’ contact details, to review notes, to flag 
patients for recontacting), and in how and whether patients’ recontacting preferences are 
recorded. 
Patients’ preferences and professionals’ responsibility    
Our findings suggest a tension between respecting patients’ preferences to not be 
recontacted (i.e., their right not to know) and the responsibility or duty of care of healthcare 
professionals towards patients and family members. Although very few clinical genetics 
services reported that they record patients’ recontacting preferences systematically, in 
response to an hypothetical question  many services responded that there were 
circumstances in which they would recontact patients and family members even if the 
patient had indicated they would not want them to do so. These circumstances were related 
to the emergence of new clinically actionable information that could have an impact on the 
patient or family members’ health management. Respondents’ views appear to be  in line 
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with the European Society of Human Genetics (ESHG) recommendations on the use of 
whole-genome sequencing in healthcare [20], in particular with the recommendation that:  
‘ Patients’ claims to a right not to know do not automatically over-ride professional 
responsibilities when the patient’s own health or that of his or her close relatives are 
at stake’ (pg.583). 
 
Implementation of recontacting  
Finally, although the majority of respondents indicated that recontacting does occur in their 
genetic centres, albeit in a non-systematic way, more than half were unsure about whether 
recontacting systems should be implemented. This finding suggests that a thorough 
evaluation of the desirability, efficacy, equitability, and sustainability of potential 
recontacting systems in the national health service would be necessary before deciding 
whether and how to implement such a service, or before suggesting guidelines. Agnosticism 
toward the implementation of recontacting systems was accompanied for some with the 
suggestion of greater patient involvement in the process of recontacting. This idea was 
supported as promoting patient autonomy while circumventing resource and infrastructural 
barriers that may prevent healthcare professionals from offering efficient recontacting 
services.  Some framed this idea as being less paternalistic than a clinician-driven 
implementation model in which the responsibility for keeping patients updated is placed 
solely on healthcare professionals. However, it is important to point out that a clinician-
driven implementation model would not be paternalistic if patients choose it.  Further, 
shifting responsibility for recontacting from clinicians to patients may be seen as promoting 
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patient choice but may not necessarily eliminate a potential duty4 clinicians could have  to 
recontact patients.    
Our data provides some insight into genetic service providers’ worries about legal 
consequences of implementing recontacting systems. Specifically, some respondents 
expressed the concern that introducing recontacting systems would create a practice 
standard and that failure to recontact could then be seen as negligent.  
It is important to point out that – although in the UK there currently is no statute law and 
professional guidance regarding recontacting, and although there have been no known 
litigation cases – the fact that some centres do recontact might be seen to create a duty to 
do so. If recontacting becomes standard practice, then patients who are not recontacted, 
and are thus not able to avail themselves of interventions that might benefit them, could 
claim that a reasonable healthcare professional should provide this service and that the 
reasonable patient could expect it. Moreover, although there are no statute law or cases 
about recontact in genetics, there have been cases in North America relevant to recontact in 
other areas of medicine [16, 17]. It is difficult to assess whether the concern towards 
potential medicolegal consequences influence healthcare professionals’ practices. We are 
exploring these issues in interviews we are currently conducting with healthcare 
professionals potentially involved in recontacting (clinical geneticists and other mainstream 
specialities) in the UK.  
LIMITATIONS 
There are some limitations to this study. Although we asked respondents to discuss the 
                                                          
4
 We follow the definition of ‘duty to recontact’ given in the first systematic review of this issue [7]. Such duty 
is defined as the ethical and/or legal obligation to recontact former patients in light of new genetic 
information.   
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questions with their centre’s clinical team before completing the survey, we cannot know 
whether they did. As genomics enters mainstream practice, it will be important to seek 
wider representations of professional views and experiences.  To address these limitations, 
we are conducting further research to investigate the views of healthcare professionals 
potentially involved in recontacting (including specialties other than clinical genetics), 
patients, and other stakeholders such as patient support groups.  
This survey was administered in the UK and reports the views and concerns of genetic 
service providers working in this country. The medicolegal aspects of recontacting and 
healthcare professionals’ views on the issue are likely to be subtly different in other 
countries, especially where legal systems are different (e.g. roman law as opposed to 
common law based systems). It will be important to conduct a wider analysis to support 
recommendations or practice guidelines, if any, in this increasingly complex area of clinical 
practice.    
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Table legend 
Table 1: most common reasons for recontacting patients and relevant family members 
(grouped by themes) 
Table 2: number of centres who ask and record patient recontacting preferences  
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Table 1. Most common reasons for recontacting patients and relevant family members 
(grouped by themes) 
Theme Quotations 
Availability of 
new genetic tests 
or new results   
“If a new (or improved) testing technique becomes available, for example 
review of patients who had limited BRCA testing, when full analysis became 
available some were recontacted and asked if they wanted a full screen” 
Family follow-up “A new family member has been referred after a long period of time, 
prompting a review of the file and recontacting the family” 
“If a result is issued on a deceased individual” 
Reclassification 
of VOUS  
 “A specific result is re-classified as more (or less) pathogenic and a clinician 
may decide to recontact a patient(s) found to have this mutation to update 
them on this new information. This is more ad hoc than systematic at the 
present time” 
New clinical 
guidance 
“New recommendations for gene carriers” 
 
Reproductive 
relevance  
“Follow up for teenager for condition of reproductive relevance” 
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Table 2. Number of centres who ask and record patient recontacting preferences  
Asking patient recontacting preferences Number 
Centres who routinely ask patients whether they would like to be recontacted 
as part of the procedure for obtaining informed consent  
8 
Centres who do not routinely ask patients whether they would like to be 
recontacted as part of the procedure for obtaining informed consent  
12 
Recording patients recontacting preferences Number 
Centres who record patient recontacting preferences – systematically  6 
Centres who record patient recontacting preferences – occasionally  6 
Centres who do not record patients recontacting preferences  8 
 
 
 
